Renwick A G, Evans S P, Sweatman T W, Cumberland J, George C F
Biochem Pharmacol. 1982 Aug 15;31(16):2649-56. doi: 10.1016/0006-2952(82)90713-4.
Sulphinpyrazone underwent both reduction to a sulphide and oxidation to a sulphone after parenteral administration to normal Wistar rats. Oral administration was associated with a bioavailability of about 75% and with a 3-fold greater formation of the sulphide. However, no sulphide was detected in the plasma after oral administration of sulphinpyrazone to germ-free (BD/X) rats or normal rats treated with oral antibiotics. In vitro studies showed that the major site of reduction of sulphinpyrazone was the contents of the hind gut with little activity detected in the liver or other tissues. The sulphide was oxidised in vivo to sulphinpyrazone and small amounts of sulphone, while the latter underwent only slight reduction to sulphinpyrazone, but did not give detectable levels of the sulphide. These data suggest that the gut microflora are the main site of reduction of sulphinpyrazone in the rat in vivo.
给正常的Wistar大鼠经肠胃外给药后,磺吡酮会发生还原反应生成硫化物,也会发生氧化反应生成砜。口服给药时,其生物利用度约为75%,生成硫化物的量会增加3倍。然而,给无菌(BD/X)大鼠或口服抗生素处理的正常大鼠口服磺吡酮后,血浆中未检测到硫化物。体外研究表明,磺吡酮还原的主要部位是后肠内容物,在肝脏或其他组织中检测到的活性较低。硫化物在体内被氧化为磺吡酮和少量砜,而后者仅轻微还原为磺吡酮,但未产生可检测水平的硫化物。这些数据表明,肠道微生物群是大鼠体内磺吡酮还原的主要部位。